for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.O

Latest Trade

252.17USD

Change

-6.44(-2.49%)

Volume

1,801,227

Today's Range

251.40

 - 

259.44

52 Week Range

177.05

 - 

264.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
258.60
Open
255.47
Volume
1,801,227
3M AVG Volume
50.53
Today's High
259.44
Today's Low
251.40
52 Week High
264.97
52 Week Low
177.05
Shares Out (MIL)
582.17
Market Cap (MIL)
150,548.80
Forward P/E
16.00
Dividend (Yield %)
2.72

Next Event

Amgen Inc WCLC Data Highlights Investor Call

Latest Developments

更多

EVOQ Therapeutics Announces A License And Collaboration Agreement With Amgen

Astrazeneca, Amgen Say Asthma Trial Did Not Meet Primary Endpoint

Amgen Says Source Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

THOUSAND OAKS, CA

91320-1730

United States

+1.805.4471000

http://www.amgen.com

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

Peter H. Griffith

Chief Financial Officer, Executive Vice President

Murdo Gordon

Executive Vice President of Global Commercial Operations

David M. Reese

Executive Vice President - Research and Development

Esteban Santos

Executive Vice President, Operations

Key Stats

2.33 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.8K

2018

23.7K

2019

23.7K

2020(E)

25.4K
EPS (USD)

2017

12.580

2018

14.400

2019

14.820

2020(E)

16.160
Price To Earnings (TTM)
20.85
Price To Sales (TTM)
6.03
Price To Book (MRQ)
13.77
Price To Cash Flow (TTM)
13.96
Total Debt To Equity (MRQ)
312.87
LT Debt To Equity (MRQ)
312.04
Return on Investment (TTM)
14.21
Return on Equity (TTM)
11.84

Latest News

Latest News

UPDATE 1-AstraZeneca-Amgen drug fails main goal of late-stage asthma study

AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.

REFILE-AstraZeneca-Amgen experimental drug fails late-stage asthma study

Drugmakers AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids while keeping the condition in check in a late-stage trial.

Amgen, AstraZeneca say experimental asthma drug meets trial goal

Drugmakers Amgen Inc and AstraZeneca Plc said on Tuesday a pivotal trial found that their experimental medication tezepelumab significantly reduced asthma attacks for people with severe forms of the respiratory condition compared to a placebo.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.

UPDATE 1-Osteoporosis drug helps Amgen third-quarter profit beat estimates

Amgen Inc on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower drug prices and COVID-19.

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Amgen Inc on Wednesday said its third-quarter adjusted profit rose 17% due to stronger sales of drugs including the osteoporosis treatment Prolia and recently-acquired psoriasis medication Otezla.

UPDATE 2-Lilly, Amgen partner to manufacture potential COVID-19 drugs

Eli Lilly and Co on Thursday partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of Lilly's drugs was shown to reduce the need for hospitalization.

Lilly partners with Amgen for manufacturing potential COVID-19 drugs

Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental COVID-19 antibody treatments.

UPDATE 2-Amgen second-quarter revenue rises 6%, shares fall 2%

Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to the new coronavirus...

Amgen second-quarter revenue rises 6%, adjusted profit tops Street view

Amgen Inc on Tuesday reported second-quarter revenue rose 6% as higher sales of newer drugs, including recently-added psoriasis treatment Otezla, offset declining sales of older medicines.

UPDATE 1-Moderna names Amgen executive David Meline as CFO

Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for COVID-19, the respiratory illness caused by the new coronavirus.

Moderna names Amgen executive David Meline as CFO

Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for the respiratory illness caused by the new coronavirus.

UPDATE 2-Amgen studying Otezla for coronavirus, looking into other treatments

Amgen Inc on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

Amgen studying Otezla for coronavirus, 1st-qtr results beat Street estimates

Amgen Inc on Thursday reported better-than-expected first-quarter results on Thursday and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

Amgen quarterly profit beats estimates, 2020 outlook falls short

Amgen Inc on Thursday said its fourth-quarter sales fell 2% due to competition from lower-cost generic drugs and biosimilars, but share buybacks enabled the company to post a profit that topped Wall Street estimates.

Amgen CEO expects 25% of growth to come from Asia in next decade

Biotechnology giant Amgen Inc expects up to a quarter of its growth to come from Asia over the next decade, Chief Executive Officer Robert Bradway told Reuters.

UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel

Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months.

UPDATE 3-Novartis takes on Sanofi, Amgen with $9.7 bln takeover of heart drug maker

Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up